AP Grigg

846 total citations
12 papers, 665 citations indexed

About

AP Grigg is a scholar working on Hematology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, AP Grigg has authored 12 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 4 papers in Oncology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in AP Grigg's work include Hematopoietic Stem Cell Transplantation (8 papers), Acute Myeloid Leukemia Research (3 papers) and Hematological disorders and diagnostics (2 papers). AP Grigg is often cited by papers focused on Hematopoietic Stem Cell Transplantation (8 papers), Acute Myeloid Leukemia Research (3 papers) and Hematological disorders and diagnostics (2 papers). AP Grigg collaborates with scholars based in Australia and Canada. AP Grigg's co-authors include Andrew W. Roberts, Jeff Szer, JE Layton, Dermot Maher, A W Boyd, S. Houghton, Jeffrey D. Zajac, Robert I. McLachlan, JD Shepherd and AC Eaves and has published in prestigious journals such as Blood, Bone Marrow Transplantation and Leukemia & lymphoma.

In The Last Decade

AP Grigg

12 papers receiving 640 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
AP Grigg Australia 10 479 197 159 113 113 12 665
G Dart Australia 9 452 0.9× 259 1.3× 102 0.6× 118 1.0× 66 0.6× 19 661
Anne M. Sproul United Kingdom 11 326 0.7× 98 0.5× 145 0.9× 107 0.9× 42 0.4× 20 531
P Buchinger Austria 13 411 0.9× 136 0.7× 196 1.2× 81 0.7× 127 1.1× 22 632
A. R. Zander Germany 8 332 0.7× 137 0.7× 186 1.2× 176 1.6× 102 0.9× 16 555
Knud Bendix‐Hansen Denmark 13 389 0.8× 169 0.9× 109 0.7× 174 1.5× 33 0.3× 28 612
Dragomir Marisavljević Serbia 16 307 0.6× 109 0.6× 104 0.7× 131 1.2× 73 0.6× 69 650
D Thorp Australia 12 621 1.3× 308 1.6× 127 0.8× 142 1.3× 50 0.4× 15 715
A. Kabral Australia 13 443 0.9× 73 0.4× 132 0.8× 76 0.7× 135 1.2× 26 610
JR Schriber United States 8 365 0.8× 212 1.1× 108 0.7× 102 0.9× 31 0.3× 9 528
CM Niemeyer United States 9 346 0.7× 114 0.6× 81 0.5× 136 1.2× 248 2.2× 15 631

Countries citing papers authored by AP Grigg

Since Specialization
Citations

This map shows the geographic impact of AP Grigg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AP Grigg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AP Grigg more than expected).

Fields of papers citing papers by AP Grigg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AP Grigg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AP Grigg. The network helps show where AP Grigg may publish in the future.

Co-authorship network of co-authors of AP Grigg

This figure shows the co-authorship network connecting the top 25 collaborators of AP Grigg. A scholar is included among the top collaborators of AP Grigg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AP Grigg. AP Grigg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Grigg, AP, John Bashford, J.F. Seymour, et al.. (2005). Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review. Leukemia & lymphoma. 46(6). 851–860. 4 indexed citations
2.
Grigg, AP, John Reynolds, Andrew McQuillan, et al.. (2004). Prognostic features for response and survival in elderly patients withde novoacute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia & lymphoma. 46(3). 367–375. 9 indexed citations
3.
Ritchie, David, Jeff Szer, Andrew W. Roberts, Paul Shuttleworth, & AP Grigg. (2002). A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. Bone Marrow Transplantation. 30(10). 645–650. 5 indexed citations
4.
Ritchie, David, P. Angus, P. S. Bhathal, & AP Grigg. (2002). Liver failure complicating non-alcoholic steatohepatitis following allogeneic bone marrow transplantation for Shwachman–Diamond syndrome. Bone Marrow Transplantation. 29(11). 931–933. 14 indexed citations
5.
Mileshkin, Linda, et al.. (2001). Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplantation. 28(12). 1145–1150. 33 indexed citations
6.
Ritchie, David, J.F. Seymour, Andrew W. Roberts, Jeff Szer, & AP Grigg. (2001). Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation. 28(1). 101–103. 49 indexed citations
7.
Grigg, AP, Robert I. McLachlan, Jeffrey D. Zajac, & Jeff Szer. (2000). Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplantation. 26(10). 1089–1095. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026